18.07.2025 17:19

Sarepta Therapeutics experienced a significant stock market downturn on Friday, with shares plummeting over 30%. This dramatic fall followed news regarding the FDA's scrutiny of their approved gene therapy, Elevidys, raising serious questions about its continued market availability.

According to sources familiar with the situation and speaking to CNBC, the FDA intends to request that Sarepta voluntarily halt all shipments of Elevidys. This action follows an ongoing investigation into two patient deaths potentially linked to the treatment. Adding to the company's woes, FDA Commissioner Marty Makary confirmed to Bloomberg News that the agency is currently evaluating the therapy's continued market viability.

Further complicating the situation, Sarepta also reported a third fatality, this time associated with a separate, experimental gene therapy. This additional death underscores the gravity of the FDA's concerns and the challenges facing the company. Attempts to obtain a statement from Sarepta were unsuccessful.

The situation remains fluid, with ongoing developments anticipated. Information from internet sources suggests this story is far from over and warrants continued monitoring for updates.